文献速递湿疹皮炎与荨麻疹银屑病与炎症性皮肤病毛发、甲与色素性疾病

OX40/OX40L调控:皮肤炎症性疾病T细胞靶向治疗新方向

OX40/OX40L modulation: A target for regulating T cells in cutaneous inflammatory disorders.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2026-04-11

本文综述OX40/OX40L轴在T细胞分化与功能中的关键作用及其作为皮肤炎症性疾病治疗靶点的潜力。相关药物在特应性皮炎中已开展试验,amlitelimab和rocatinlimab显示一定疗效且应答更持久,但拮抗剂的广泛免疫抑制与激动剂可能加重疾病的风险仍需进一步研究。

要点

  • OX40/OX40L是T细胞分化与功能的关键轴,为T细胞驱动性皮肤病提供新靶点
  • amlitelimab和rocatinlimab在特应性皮炎中显示疗效且应答更持久
  • 拮抗剂广泛免疫抑制与激动剂加重疾病的风险需真实世界研究评估

核心结论

  • OX40/OX40L是有前景的T细胞驱动性皮肤炎症性疾病治疗靶点
  • amlitelimab和rocatinlimab显示一定疗效且应答更持久
  • 该类药物需进一步研究确定真实世界获益风险比

研究设计与样本

  • 综述性文章,未报告系统检索范围与样本量

主要发现

  • OX40/OX40L已被确认为T细胞分化与功能的关键轴
  • OX40/OX40L激动剂与抑制剂在特应性皮炎、斑秃、银屑病等疾病中有潜在用途
  • 相关药物试验主要在特应性皮炎中开展,但在其他皮肤病中也显示前景

临床怎么用

  • 关注OX40/OX40L靶向药物在特应性皮炎等T细胞驱动性皮肤病中的应用前景
  • 使用拮抗剂时警惕广泛免疫抑制风险,使用激动剂时警惕疾病加重风险

局限性

  • 相关药物试验主要在特应性皮炎中开展,其他皮肤病证据有限
  • 真实世界获益风险比尚待进一步研究确定

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The aetiology of many inflammatory cutaneous diseases is T cell-driven and involves dysregulation of the immune response. The complex nature of the immune system's involvement in these diseases has made the development of effective, safe, and durable treatments challenging, resulting in a continued demand for the development of novel therapeutics. OX40 and its ligand OX40L have been previously identified as a crucial axis in T cell differentiation and function, and are promising targets for the treatment of T cell-driven disease. Development of OX40/OX40L agonists and inhibitors has potential uses in atopic dermatitis, alopecia areata, psoriasis, and more. While trials of these drugs have mainly been conducted in atopic dermatitis, they show promise in treating other dermatological conditions. Studies of amlitelimab and rocatinlimab have shown some efficacy but have demonstrated increased durability of response. Current concerns with the class are the potential for broad immune suppression with antagonists and the potential for worsening disease with agonists. Additional studies will enable us to determine their benefit-risk ratio in the real-world setting.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Gupta AK, Steriopoulos J, Economopoulos V, et al. OX40/OX40L modulation: A target for regulating T cells in cutaneous inflammatory disorders. J Eur Acad Dermatol Venereol. 2026. PMID: 41964298. doi:10.1111/jdv.70443

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。